9-Me-BC vs DNSP-11
Limited Research vs Limited Research
compatible Both target dopaminergic neuron health. 9-Me-BC promotes dendrite growth and dopamine synthesis; DNSP-11 provides neurotrophic protection.
Molecular Data
9-Me-BC DNSP-11
Weight 182.22 Da ~1200 Da
Half-life Not well characterized in humans Not well characterized
Chain — 11 amino acids
Type Beta-carboline derivative (C12H10N2) GDNF pro-domain derived peptide
Key Benefits
9-Me-BC
01 Upregulates tyrosine hydroxylase expression, enhancing endogenous dopamine synthesis capacity
02 Promotes dopaminergic neuron differentiation and neurite outgrowth in preclinical models, suggesting genuine neurorestorative potential
03 Anti-inflammatory effects on microglia may protect dopaminergic neurons from neuroinflammatory damage
04 Potential application in restoring dopaminergic function after stimulant-induced downregulation or neurotoxic damage
05 Low effective dose (milligram range) compared to many other nootropic compounds
DNSP-11
01 Protects dopaminergic neurons from neurotoxic insults
02 Stimulates dopamine production via tyrosine hydroxylase upregulation
03 Smaller molecule with improved bioavailability compared to full GDNF
04 Does not require GFRalpha1/RET receptor complex for activity
05 Preclinical evidence for neuroprotection in Parkinson's disease models
06 Compatible with intranasal and subcutaneous administration
Dosing Protocols
9-Me-BC
5-15 mg/day / Once daily (morning, sublingual)
DNSP-11
100-200mcg per day / 1x daily (morning recommended)
General neuroprotection 100-200mcg 1x daily
Side Effects
9-Me-BC
Severe photosensitivity -- CRITICAL: skin becomes highly reactive to UV radiation during use, with risk of exaggerated sunburn, phototoxic skin reactions, and UV-induced DNA damage
Insomnia or sleep disruption (mitigated by morning-only dosing)
Mild headache during the first few days of use
DNSP-11
Nasal irritation or mild burning sensation (intranasal route)
Injection site reactions such as redness or swelling (subcutaneous route)
Contraindications
Inability to strictly avoid sun and UV exposure for the duration of use -- this is an absolute contraindication due to the risk of phototoxic DNA damage
Concurrent use of MAO inhibitors
Pregnancy and breastfeeding (no safety data available)
History of photosensitivity disorders or skin cancer
Concurrent use of other photosensitizing medications (tetracyclines, fluoroquinolones, thiazides, etc.)
Pregnancy or breastfeeding
Known peptide allergies
Very limited human safety data; use at own risk
Consult a physician before combining with dopaminergic medications
Research Evidence
9-Me-BC DNSP-11
Status Limited Research Limited Research
References 5 studies 4 studies
Latest — 2014
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.